Drugs that contain Oxymetazoline Hydrochloride
1. Rhofade patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8815929 | MAYNE PHARMA | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
Jan, 2024
(3 months ago) | |
| US8420688 | MAYNE PHARMA | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
Aug, 2024
(3 months from now) | |
| US7812049 | MAYNE PHARMA | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
May, 2028
(4 years from now) | |
| US8883838 | MAYNE PHARMA | Pharmaceutical cream compositions and methods of use |
Dec, 2031
(7 years from now) | |
| US10335391 | MAYNE PHARMA | Stabilized oxymetazoline formulations and their uses |
Jun, 2035
(11 years from now) | |
| US9974773 | MAYNE PHARMA | Stabilized oxymetazoline formulations and their uses |
Jun, 2035
(11 years from now) | |
| US10751325 | MAYNE PHARMA | Stabilized oxymetazoline formulations and their uses |
Jun, 2035
(11 years from now) | |
| US11517560 | MAYNE PHARMA | Stabilized oxymetazoline formulations and their uses |
Jun, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 18, 2020 |
Market Authorisation Date: 18 January, 2017
Treatment: Topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream; Once daily topical treatment of persistent facial erythema associated with ...
Dosage: CREAM;TOPICAL
RHOFADE family patents
2. Upneeq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10912765 | RVL PHARMS | Compositions and methods for non-surgical treatment of ptosis |
Aug, 2031
(7 years from now) | |
| US8357714 | RVL PHARMS | Compositions and methods for non-surgical treatment of ptosis |
Aug, 2031
(7 years from now) | |
| US9867808 | RVL PHARMS | Compositions and methods for non-surgical treatment of Ptosis |
Aug, 2031
(7 years from now) | |
| US11103482 | RVL PHARMS | Oxymetazoline compositions |
Dec, 2039
(15 years from now) | |
| US11701343 | RVL PHARMS | Compositions and methods for treating ocular disorders |
Dec, 2039
(15 years from now) | |
| US10940138 | RVL PHARMS | Compositions and methods for treating ocular disorders |
Dec, 2039
(15 years from now) | |
| US10814001 | RVL PHARMS | Oxymetazoline compositions |
Dec, 2039
(15 years from now) | |
| US11311515 | RVL PHARMS | Oxymetazoline compositions |
Dec, 2039
(15 years from now) | |
| US11324722 | RVL PHARMS | Compositions and methods for treating ocular disorders |
Dec, 2039
(15 years from now) | |
| US11541036 | RVL PHARMS | Oxymetazoline compositions |
Dec, 2039
(15 years from now) | |
| US10898573 | RVL PHARMS | Oxymetazoline compositions |
Dec, 2039
(15 years from now) | |
| US10799481 | RVL PHARMS | Compositions and methods for treating ocular disorders |
Dec, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 08, 2023 |
Market Authorisation Date: 08 July, 2020
Treatment: Method of treating blepharoptosis
Dosage: SOLUTION/DROPS;OPHTHALMIC
UPNEEQ family patents